We screened human prostate cancer tissues for the presence of somatic mutations in the hormone binding domain of the androgen receptor (AR) gene. Exons E-H were amplified from genomic DNA using the polymerase chain reaction and analyzed by denaturing gradient gel electrophoresis (DGGE), which separates DNA fragments that differ by only a single base. We detected a mutation in exon E of the hormone binding domain in 1 of 26 specimens of untreated organ-confined stage B prostate cancer. The mutation was not detectable in peripheral blood lymphocyte DNA. Lymphocyte DNA (wild-type AR) migrated in DGGE as a single band. The tumor DNA migrated in DGGE as four bands, consistent with the presence of cells with mutant AR plus cells with wild-type AR and indicating that the tumor contained a somatic mutation. To our knowledge, a somatic AR gene mutation has not been reported previously. Sequencing revealed a G --A substitution in codon 730, changing valine to methionine. Codon 730 is in a region highly conserved among all steroid receptors. The abundance of the mutated fragment (about 50% of the DNA in the specimen) indicates its presence in cells with a growth advantage. A somatic mutation could be detected by DGGE if it represented at least 10% of the sample. Failure to detect mutations in other specimens analyzed may be due to this limit of sensitivity, the presence of mutations in other parts of the AR, or a low frequency of mutations in early stage disease.
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Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer deaths in men in the U.S. (1) . Recognition that androgen is required for the development of prostate cancer (2) and its growth (3) has been the basis for continuing interest in the role of the androgen receptor (AR) in prostate cancer (1, (4) (5) (6) . The AR is a member of the superfamily of genes that code for the steroid and thyroid hormone receptor family of ligand-dependent nuclear transcription factors, all of which have an N-terminal domain that affects transcription efficiency, a central DNA binding domain that binds to a target gene hormone response element and thereby determines target gene specificity, and a C-terminal hormone binding domain (HBD) (7) (8) (9) . Studies on the role of AR in prostate cancer have focused on measurements of AR based on ligand binding or immunohistochemistry (4) (5) (6) . However, it is now clear that ligand binding and immunoreactivity are not adequate indicators of a functional AR, since mutant ARs can be generated that bind steroid but are nonfunctional or that do not bind steroid but are nevertheless constitutively active (10) (11) (12) . Deletion of all or part of the N-terminal domain or of the DNA binding domain renders the AR transcriptionally inactive despite its ability to still bind androgen with high affinity (11, 12) . Most remarkably, deletion of the HBD renders the AR unable to bind steroid but constitutively transcriptionally active even in the absence of hormone (10) (11) (12) . Thus, knowledge of the integrity of the AR gene or gene product may be a more accurate index of potential AR function in prostate cancer than immunoreactivity or ligand binding.
Mutated ARs occur naturally as a result of AR gene mutations (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . AR gene mutations were first described in complete androgen insensitivity syndrome (CAIS), an X chromosome-linked inherited disorder that causes XY genotypic males to develop as phenotypic females because of defective AR (13) (14) (15) (16) (17) (18) . AR gene mutations in CAIS have been found in the N-terminal domain (17, 18) , the DNA binding domain (17) , or the HBD (13) (14) (15) (16) (17) . Each of these mutations inactivates AR function, even though some of the mutant AR proteins produced still bind androgen (15) (16) (17) .
Not all naturally occurring AR gene mutations inactivate AR function, as first documented in a human prostate cancer cell line (21, 22) . The LNCaP human prostate cancer cell line is androgen independent (23, 24) , but growth in vitro can be stimulated by androgen, estrogen, progesterone, or antiandrogen (21, 22) . These cells contain AR but no estrogen receptors or progesterone receptors; however, the AR gene contains a point mutation in the HBD that converts a threonine to alanine (21, 22) . The position of this mutation was reported by Harris et al. (21) to be codon 877 of a 919 codon AR cDNA (7, 14, 21) and by Veldscholte et al. (22) to be codon 868 of a 910 codon AR cDNA (12, 22) ; these are equivalent positions. Remarkably, this mutant AR has altered steroid specificity compared to wild-type AR; mutant AR binds and is transcriptionally activated by androgen, estrogen, progesterone, or antiandrogen (21, 22) . Although the possibility has not been ruled out that this AR gene mutation occurred during establishment of the LNCaP cell line in vitro, the mutation might well have accounted for growth of the androgen-independent lymph node metastasis from which the LNCaP cells were aspirated after estrogen therapy (23 (24) were also studied. Amplification of Genomic DNA by the Polymerase Chain Reaction (PCR). Genomic DNA was isolated (25) . AR exons E-H plus their intron/exon borders were amplified from genomic DNA by PCR using oligonucleotide primers designed to permit detection of splice site and coding sequence mutations (14) and modified to include a 40-nucleotide GC tail at the 5' end of each 5' primer (15) . These GC tails become amplified during PCR and create a 5' GC clamp that resists strand separation in denaturing gradient gel electrophoresis (DGGE) and increases the resolution of mutations in DGGE (26) . PCR conditions were as described (15 (26) . Gels were stained with ethidium bromide.
DNA Sequencing. DNA was amplified using primers without a GC tail (14, 15) and direct sequencing of PCR products was carried out using the dideoxynucleotide chaintermination method (15, 27) . The sense and antisense strands were sequenced. (26) . The presence of more than one allele in the same specimen was evidence that the tumor contained a somatic mutation. The presence of a mutation in patient no. 7 exon E was confirmed by independent amplifications of additional aliquots of genomic DNA cancer caused a change in the amino acid coding sequence or changed the splice site sequence. Exon E was amplified from another aliquot of genomic DNA, and the PCR product was sequenced directly (15, 27) . The DNA sequence of exon E from normal peripheral blood lymphocytes of the same patient (Fig. 4) was identical to that of wild-type AR (14) . In contrast, the sequencing gel of the tumor exon E revealed the presence of two bases, G and A, at the first nucleotide position of codon 730 (using the numbering in ref.
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14) (Fig. 4) . This is consistent with the presence of two DNA fragments that have a different sequence, again diagnostic of the presence of a somatic mutation. The wild-type AR codon 730 is GTG, which codes for valine; the presence of A at the first position changes the sequence to ATG, which codes for methionine (Fig. 4) . Sequencing of the opposite DNA strand confirmed these results. All other nucleotides were identical to wild type, indicating that tumor exon E differed from normal by only a single base substitution. These data attest to the sensitivity of detecting a DNA sequence alteration by DGGE. Fig. 1 illustrates the position of this mutation in the coding sequence of the AR and shows the surrounding sequence in the human AR and in the equivalent sequences of other members of the steroid receptor family, including the progesterone receptor, glucocorticoid receptor, mineralocorticoid receptor, and estrogen receptor (7) . AR codon 730 is located in a region of the HBD that is highly conserved among members of the steroid receptor family, but the amino acid at codon 730 is unique to the AR.
Sequencing of the mutation in patient no. 7 stage B prostate cancer revealed that it disrupted a Pml I restriction site. Exon E of wild-type AR contains only one Pml I site (14) ; therefore Pml I digestion of wild-type PCR product [327 base pairs (bp)] should yield two bands, 109 bp and 218 bp, but Pml I should not digest the mutant 327-bp fragment. Pmi I digestion of the exon E PCR product from normal peripheral lymphocyte DNA of patient no. 7 indeed yielded two bands as expected (Fig. 5, lane 4) . Pml I digestion of the prostate cancer exon E yielded three bands: a 327-bp band that resisted digestion (Fig. 6) . Mixtures of wild type and mutant gave rise to multiple bands in DGGE, as expected, and these could be seen when 10% of the sample contained a mutation (Fig. 6) . Because (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . In our study, we were able to screen for the presence of mutations in large numbers of prostate cancer specimens having unknown AR properties by analyzing the mobility of PCR-amplified DNA fragments in DGGE. Only DNA fragments that have a mobility different from that of wild type are sequenced.
Our ability to detect mutations depends not only on the use of optimal conditions of DGGE but also on the proportion of the sample that contains mutant DNA and on the sensitivity of detecting that DNA. Using ethidium bromide staining of DGGE gels, we can detect the presence of a mutation if it represents at least 10%6 of the sample. Since all tumors contain nonmalignant supporting stroma and blood vessels, detection of a somatic mutation depends on the proportion of tumor and nontumor cells in the specimen and on the proportion of tumor cells with the mutation. Detection of multiple bands by DGGE, though diagnostic of a somatic mutation, does not indicate whether the wild-type allele is present in malignant cells that lack the mutation, in nonmalignant cells, or in both.
With this approach we identified an AR gene mutation in a specimen of stage B prostate cancer, which we diagnosed based on the presence of multiple bands in DGGE. The mutation was not detectable in peripheral blood lymphocyte DNA. Therefore, the tumor contained a somatic mutation. Finding an AR gene mutation in a surgical specimen of untreated, organ-confined stage B disease raises the question whether mutated AR might have oncogenic potential, as appears to be the case for the v-erbA oncogene, which is a truncated mutant of the thyroid hormone receptor gene (9, 28) , and the translocated chimeric retinoic acid receptor a in acute promyelocytic leukemia (29) . Alternatively, mutated AR in untreated stage B cancer might reflect progression to androgen independence, which is believed to occur prior to androgen ablation (30 (11, 12) , a dimerization domain (11, 12, 28, 29) , hsp90 interaction domain(s) (7, 32) , and transcription activation domains (9, (10) (11) (12) (15) (16) (17) (28, 29, 34) .
The mutation at AR codon 730 is in a conserved region of the HBD involved in binding to ligand and to hsp90 (7, 32 (21, 22) , CAIS (13) (14) (15) (16) (17) (18) , hypospadias (20) , and X chromosome-linked spinal and bulbar muscular atrophy (19) , naturally occurring mutations also have been found recently in other members of the steroid receptor superfamily: estrogen receptors in human breast cancer (34) , vitamin D receptors in hereditary rickets (35) , retinoid receptors in acute promyelocytic leukemia (29) , glucocorticoid receptors in glucocorticoid-resistant cells (36) , and thyroid hormone receptors in thyroid hormone resistance syndrome (37) . Nota- bly, an estrogen receptor mRNA variant has been found in breast cancer that lacks part of the HBD (34); remarkably, it yields a mutant receptor that is constitutively active in the absence of estrogen (34) , providing a potential mechanism for estrogen-independent breast cancer growth. Mutations in other important signal transducing molecules confer oncogenic potential-for example, (i) mutated plasma membraneassociated GTP-binding proteins G, and Gja are oncogenes (38) ; (ii) mutated a1B-adrenergic receptors enhance mitogenesis and tumorigenicity (39) ; (iii) the v-erbA oncogene is a truncated and mutated form of the thyroid hormone receptor gene (6, 28) ; and (iv) ras gene mutations are oncogenic (40 (1, 3) , the requirement of androgen for prostate carcinogenesis (2) , and the persistent expression of AR in androgen-independent prostate cancer (6, 21, 22) , which raises the possibility of continued AR activity even in the absence of androgen, it is tempting to hypothesize that mutations in the AR gene might be involved in the development or progression of prostate cancer. Our discovery of a somatic AR gene mutation in early stage prostate cancer, even prior to androgen ablation, warrants further investigation of this hypothesis.
